Introduction
Hirano bodies are rod-shaped, eosinophilic, cytoplasmic inclusions ( Figure 1a ) consisting of lattice-like aggregates of parallel ®laments approximately 10 nm in diameter [12, 34, 38] . They are found preferentially in neuronal processes in the hippocampal CA1 stratum pyramidale with increasing age and in a variety of neurodegenerative disorders, including Alzheimer's disease [10] . They can also be found in the CA1 stratum lacunosum, where their numbers peak during middle-age and subsequently decline [15, 25, 33] . Hirano bodies consist mostly of F-actin and actin-associated proteins [6, 9] . They also contain microtubule associated proteins [7, 27] , neuro®-lament epitopes [33] , C-terminal fragments of b-amyloid [24] , hippocampal cholinergic neurostimulating peptide [22] , advanced glycation endproducts [23] and FAC1 protein [13] . Hirano bodies likely represent alteration of the micro®lamentous cytoskeleton [10, 13] , perhaps related to changes in the septo-hippocampal cholinergic system [20, 22] .
Activation of a family of cysteinyl aspartate-speci®c proteases (caspases) has recently been identi®ed as a central feature of apoptotic cell death [37] . Caspase activation results in proteolytic cleavage of multiple intracellular structural and functional substrates at speci®c aspartate residues, including actin micro®la-ments [4, 16, 19] . Caspase-3, which is activated by proteolysis of its zymogen into p18 and p12 subunits, appears to be an especially important apoptosis effector molecule [4, 28] . A rabbit polyclonal antiserum, CM1, which speci®cally recognizes the p18 subunit of activated caspase-3, but not the inactive zymogen, has recently been characterized [35] . Furthermore, identi®cation of caspase cleavage of actin into N-terminal y32 kDa and C-terminal y15 kDa fragments in apoptotic cell extracts [14, 18] has led to the development of an end-speci®c rabbit polyclonal antibody directed to b-actin residues 240±244 (YELPD), representing the ®ve C-terminal residues of the y32 kDa fragment generated by cleavage at aspartate 244 (Figure 1b) [36, 39] . This fractin (fragment of actin) antibody speci®cally recognizes caspase-cleaved, but not intact actin. It labels apoptotic, but not necrotic, neuroblastoma cells in vitro and also the cell bodies and processes of plaque-associated neurones and microglia in Alzheimer's disease brain [39] .
In the present study, fractin and CM1 immunohistochemistry were performed on hippocampal sections from Alzheimer's and non-demented control cases containing numerous Hirano bodies. Part of this work has previously been presented in abstract form [31] .
Materials and methods
Paraf®n-embedded hippocampal sections (7 mm) containing numerous Hirano bodies in the CA1 pyramidal layer were used in this study. This material was prepared from formalin-®xed post-mortem brain tissue from ®ve neuropathologically con®rmed Alzheimer's disease cases (70±88-year-old) and two non-demented controls (70 and 76 years).
The sections, mounted on charged slides, were deparaf®nized in toluene and endogenous peroxidase activity was quenched in 0.35% H 2 O 2 /methanol for 1 h at room temperature (RT). Microwave antigen retrieval [3] was performed in 0.01 M citric acid (pH 6.0) maintained at close to boiling point for 30 min (it has been previously established that such antigen retrieval is essential for detection of cleaved actin in apoptotic cells in paraf®n embedded human [30, 36] and rodent tissues, but not in frozen tissue sections [32, 39] . This is also the case for immunodetection of activated caspase-3 with the CM1 polyclonal antiserum). Following cooling and brief water and phosphate-buffered saline (PBS) washes, the sections were incubated in a blocking solution containing 2% normal goat serum, 0.5% bovine serum albumin (BSA) and 0.01% Triton X-100 in PBS for 1 h at RT in a humidi®ed chamber.
The sections were then incubated for 24 h at 4uC with (a) af®nity-puri®ed rabbit polyclonal fractin antibody or (b) fractin antiserum or (c) CM1 antiserum, diluted (i) 1:50 (ii) 1:1000 and (iii) 1:500, in the above blocking solution, washed in 0.05% Tween-20 in PBS and then incubated for 3 h at RT in biotinylated anti-rabbit secondary antibody (Vector, Burlingame, CA, USA; 1:500). Following further washes, the sections were incubated with Vectastain Elite ABC reagents (Vector; 1:100) for 2 h at RT, washed and reacted with 0.025% diaminobenzidine (DAB) and 0.05% H 2 O 2 in Trisbuffered saline for 12 min. The sections were lightly counterstained with haematoxylin.
As negative controls (i) the primary fractin or CM1 antibody was omitted from the incubation for some sections, or (ii) in the case of fractin, the af®nity-puri®ed primary antibody or antiserum was pre-absorbed with a 10-fold excess by weight of the free YELPD peptide antigen. As positive controls, paraf®n-embedded brainstem sections containing apoptotic pontine neurones from post-mortem cases of acute perinatal hypoxic± ischaemic brain injury [30] were used.
Results
Numerous fractin-positive Hirano bodies were seen in the CA1 stratum pyramidale of all the Alzheimer's disease and non-demented control cases, on sections immunolabelled with either the polyclonal fractin antiserum (Figure 1c) , or the af®nity-puri®ed polyclonal fractin antibody (Figure 1d) . There was no labelling on adjacent negative control sections where the primary antiserum/ antibody had been omitted, or preabsorbed with the free YELPD peptide antigen (Figure 1e ). On positive control sections of neonatal brain stem, there was strong fractin labelling of apoptotic, but not intact, nuclei pontis neurons (Figure 1f) . At higher power magni®cation (Figure 1g±j ), the Hirano bodies exhibited moderate to intense diffuse fractin immunoreactivity. Fractin labelled Hirano bodies were also seen in the CA1 stratum lacunosum of several cases. On sections immunostained with the CM1 antibody to activated caspase-3 there was no evidence of labelling of Hirano bodies, although apoptotic neurones in the control brainstem sections showed strong immunoreactivity (not shown). The end-speci®c fractin polyclonal antibody was generated by injecting rabbits with synthetic b-actin residues 240±244, coupled via a K residue (K-YELPD) to a carrier protein (puri®ed derivative of tuberculin) [39] . (c) Hirano bodies immunolabelled with fractin antiserum (1:1000) and (d) af®nity-puri®ed polyclonal fractin antibody (1:50). (e) Negative control; absence of fractin labelling on adjacent section following pre-absorbtion of the primary fractin antibody with the YELPD antigen. (f) Positive control; fractin-immunolabelled apoptotic neurons in the nuclei pontis from a post-mortem case of acute perinatal hypoxic±ischaemic brain injury. (g±j) Representative high-power views of fractin-immunolabelled Hirano bodies (fractin antiserum, 1:1000). ar1400; c±er220; fr900; g±ir1000; jr800. Photographed with Nomarski optics.
Discussion
The lattice-like ®lamentous aggregates comprising Hirano bodies likely consist predominantly of actin and actin-associated proteins [7, 9, 10, 15] . The diffuse immunoreactivity of Hirano bodies with the fractin polyclonal antibody, speci®c for a neo-epitope at a caspase-cleavage site, shows that the actin is, at least in part, proteolytically altered. This ®nding suggests that caspase-like cleavage of the actin micro®lamentous network may play a role in the formation of Hirano bodies. Interestingly, low level expression of the caspase generated C-terminal 15 kDa portion of actin has recently been shown to induce marked condensation and partial fragmentation of the endogenous actin network in cultured 293T embryonic kidney cells [19] . Alternatively, a proteolytic process directed at degrading pre-existing Hirano bodies may generate fractin.
Hirano bodies are likely located predominantly within neurites [10] . Consequently, their fractin immunoreactivity supports caspase-like activity within neuronal processes, as distinct from that associated with acute perikaryal apoptosis. This is consistent with increasing evidence for a role of localized caspase activation in neuritic degeneration (`neuritic/synaptic apoptosis') in Alzheimer's disease [8, 11, 21, 39] .
There are several potential explanations for the lack of immunolabelling of Hirano bodies with the CM1 antibody to activated caspase-3: the enzyme cleavage product of an abundant substrate such as actin is likely to be much more prevalent than the enzyme itself, so the concentration of caspase-3 may be too low to detect by immunohistochemistry; the actin cleavage may all have occurred at an earlier time and/or at a different location, such as the neuronal perikaryon, or the cleavage may be mediated by a different member of the caspase family. Alternatively, the presence of a cleavedactin epitope in Hirano bodies may re¯ect the activity of a non-caspase enzyme. The lysosomal aspartyl protease cathepsin D is upregulated in Alzheimer's disease [1, 2] and could potentially generate the fractin epitope by directly cleaving actin, or indirectly by activating caspase cascades, as there is increasing evidence of it having a causal role in apoptotic pathways [5, 17, 26, 29] . In conclusion, the present ®ndings indicate that Hirano bodies are composed, at least in part, of proteolytically cleaved actin.
